Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

InterMune ASCENDs on new Phase III pirfenidone data

26.02.2014 / Scripintelligence

Brisbane, California-based InterMune's stock soared 170.8% higher on 25 February to close at $37.80 per share with a $3bn market cap after the company said pirfenidone cut the percentage of IPF patients who died or experienced a 10% decrease in lung…

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: